Company
Headquarters: West Conshohocken, PA, United States
Employees: 71
CEO: Dr. Paul A. Friedman M.D.
$6.64 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-à agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $317.4 M |
EBITDA | $-423,841,984 |
Gross Profit TTM | $306.6 M |
Profit Margin | -123.38% |
Operating Margin | -57.79% |
Quarterly Revenue Growth | 32.84% |
Madrigal Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: MDGL wb_incandescent
Stock: FSX: YDO1 wb_incandescent